[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-60;  61-80;   81-100101-120121-140141-160;  161-180181-200201-220221-240241-260261-280; 281+

NICE TAs 21-40

 

REF

 

TITLE

 

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

TA21

Diabetes (type 2) - pioglitazone (TA21) (replaced by TA63) (withdrawn)                       

Withdrawn                                    

                          

 TA22

Obesity - orlistat (TA22) (replaced by CG43) (withdrawn)

Withdrawn

 

 TA23

Brain cancer - temozolomide (TA23)

 

EMCN algorithm

DHFT protocol

 TA24

Wound care - debriding agents (TA24) (replaced by CG74)

Withdrawn

 

 TA25

Pancreatic cancer - gemcitabine (TA25)

 

EMCN algorithm

DHFT protocol

 TA26

Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine (TA26) (replaced by CG24)

Withdrawn

 

 TA27

Osteoarthritis and rheumatoid arthritis - cox II inhibitors (TA27) (replaced by CG59 and CG79) (withdrawn)

Withdrawn

 

 TA28

Ovarian cancer - topotecan (TA28) (replaced by TA91) (withdrawn)

Withdrawn

 

 TA29

Leukaemia (lymphocytic) - fludarabine (TA29)

 

EMCN algorithm

DHFT protocol

 TA30

Breast cancer - taxanes (review) (TA30) (replaced by CG81)

Withdrawn

 

 TA31

Obesity - sibutramine (TA31) (replaced by CG43) (withdrawn)

Withdrawn

 

 TA32

Multiple sclerosis - beta interferon and glatiramer acetate (TA32)

8.2 Drugs affecting the immune response: 8.2.4 Other Immunomodulating Drugs

 

 TA33

Colorectal cancer (advanced) - irinotecan, oxaliplatin & raltitrexed (TA33) (replaced by TA93) (withdrawn)

Withdrawn

 

 TA34

Breast cancer - trastuzumab (TA34)

 

EMCN algorithm

DHFT protocol

 TA35

Arthritis (juvenile idiopathic) - etanercept (TA35)

10.1.3 Drugs which suppress the rheumatic disease process

 

 TA36

Rheumatoid arthritis - etanercept and infliximab (TA36) (replaced by TA130 and TA195)

Withdrawn

 

 TA37

Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137) (TA37) (replaced by TA137) (withdrawn)

Withdrawn

 

 TA38

Asthma (older children) - inhaler devices (TA38)

3.1 Bronchodilators

 

 TA39

Smoking cessation - bupropion and nicotine replacement therapy (TA39) (replaced by PH10) (withdrawn)

Withdrawn

 

 TA40

Crohn's disease - infliximab (TA40) (replaced by TA187)

Withdrawn

 

 

 

 

 

 

 

 

 

: